UY34812A - Método para el tratamiento del cáncer de pulmón de células no pequeñas - Google Patents

Método para el tratamiento del cáncer de pulmón de células no pequeñas

Info

Publication number
UY34812A
UY34812A UY0001034812A UY34812A UY34812A UY 34812 A UY34812 A UY 34812A UY 0001034812 A UY0001034812 A UY 0001034812A UY 34812 A UY34812 A UY 34812A UY 34812 A UY34812 A UY 34812A
Authority
UY
Uruguay
Prior art keywords
treatment
lung cancer
small cells
cells
small
Prior art date
Application number
UY0001034812A
Other languages
English (en)
Inventor
Duksin Chen
Tessler Shoshi
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of UY34812A publication Critical patent/UY34812A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona métodos para el tratamiento de un paciente quien padece cáncer de pulmón d e células no pequeñas metastásico o avanzado, no resecable, cuyos métodos comprenden administrar al paciente quimioterapia que comprende una cantida d de docetaxel y 640 mg de un oligonucleótido anti-clusterina que tiene la secuencia CAGCAGCAGAGTCT TCATCAT donde el oligonucleótido anti-clusterina tiene una columna vertebral fósforotioato a su través, tiene mitades de azúcar de los nucleótidos 1 -4 y 18-21 que portan modificaciones 2´-O-metoxietilo,los nucleótidos 5-17 que son 2´desoxinucleóti dos y 5-metilcitosinas en los nucleótidos 1, 4 y 19. La invención proporciona composiciones, combin aciones, paquetes y usos de los mismos
UY0001034812A 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas UY34812A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
UY34812A true UY34812A (es) 2013-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034812A UY34812A (es) 2012-05-18 2013-05-16 Método para el tratamiento del cáncer de pulmón de células no pequeñas

Country Status (17)

Country Link
US (1) US20130310440A1 (es)
EP (1) EP2849761A1 (es)
JP (1) JP2015522542A (es)
KR (1) KR20150024843A (es)
CN (1) CN104684564A (es)
AR (1) AR091090A1 (es)
AU (1) AU2013262589A1 (es)
BR (1) BR112014028787A2 (es)
CA (1) CA2874092A1 (es)
EA (1) EA201492148A1 (es)
IL (1) IL235459A0 (es)
IN (1) IN2014DN10390A (es)
PH (1) PH12014502569A1 (es)
SG (1) SG11201407649RA (es)
TW (1) TW201402132A (es)
UY (1) UY34812A (es)
WO (1) WO2013173757A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534773B1 (en) 1999-02-26 2009-05-19 The University Of British Columbia TRPM-2 antisense therapy
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP4335362A1 (en) 2010-05-08 2024-03-13 The Regents of The University of California Method and apparatus for early detection of ulcers by scanning of subepidermal moisture
JP2014509608A (ja) 2011-03-15 2014-04-21 ザ ユニバーシティ オブ ブリティッシュ コロンビア 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとhsp90阻害剤との併用
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
KR102283395B1 (ko) 2017-02-03 2021-07-30 브루인 바이오메트릭스, 엘엘씨 당뇨병성 족부 궤양에 대한 감수성의 측정
JP7015305B2 (ja) 2017-02-03 2022-02-02 ブルーイン、バイオメトリクス、リミテッド、ライアビリティー、カンパニー 組織生存度の測定
CN109890273B (zh) 2017-02-03 2022-10-11 布鲁恩生物有限责任公司 水肿的测量
CA3080407A1 (en) 2017-11-16 2019-05-23 Bruin Biometrics, Llc Providing a continuity of care across multiple care settings
US20190211044A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant Chemicals that Prevent Drug Tolerance and Persister Formation by Bacteria
EP3749181B1 (en) 2018-02-09 2024-02-21 Bruin Biometrics, LLC Detection of tissue damage
GB2591899B (en) 2018-10-11 2022-03-09 Bruin Biometrics Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
WO2005094899A1 (en) * 2004-04-02 2005-10-13 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ PlGF−1コンパニオン診断方法および製品
AU2012257487A1 (en) * 2011-05-19 2014-01-16 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
EP2849761A1 (en) 2015-03-25
IN2014DN10390A (es) 2015-08-14
US20130310440A1 (en) 2013-11-21
IL235459A0 (en) 2014-12-31
CN104684564A (zh) 2015-06-03
PH12014502569A1 (en) 2015-01-21
SG11201407649RA (en) 2014-12-30
WO2013173757A8 (en) 2015-04-30
AR091090A1 (es) 2014-12-30
CA2874092A1 (en) 2013-11-21
AU2013262589A1 (en) 2015-01-22
KR20150024843A (ko) 2015-03-09
TW201402132A (zh) 2014-01-16
WO2013173757A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
JP2015522542A (ja) 2015-08-06
BR112014028787A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
IL288181A (en) Cancer treatment methods
IL272905A (en) Methods of treating pancreatic cancer
IL236336A0 (en) Methods of treating breast cancer with gemcitabine therapy
IL237791A0 (en) A method for treating cancer
SG11201605585SA (en) Targeted therapy for small cell lung cancer
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
BR112014032105A2 (pt) método para o tratamento de câncer
SG11201503893RA (en) Method of treating cancer
UY34661A (es) Inhibidores de benzodioxano de la producción de leucotrieno para terapia de combinación
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
HK1211322A1 (en) Methods of treating pancreatic cancer
HK1205254A1 (en) Methods of treatment of cancer
BR112014027219A2 (pt) método
BR112014026326A2 (pt) composição para tratamento de distúrbios metabólicos
EP3252171B8 (en) Methods of treating cancer
UY34604A (es) Inhibidores de oxadiazol de la producción de leucotrienos para terapia de combinación
UY34277A (es) Metodo para la eliminación del naftaleno
IL237229A0 (en) Methods of treating cancer using lipoplatin
BR112015008366A2 (pt) método de tratamento de câncer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528